Senses Disorder TRIZ Cases

Nasal mucosa irritation from aqueous solutions stimulates endogenous nerve growth factor production, overcoming blood-brain barrier limitations.

IGFBP3-Fc fusion protein binds multiple growth factors to inhibit tumor cell proliferation, preventing resistance development from bypass signaling pathways.

Mutations in the Fc region lower serum export rates, allowing high intracranial IL-12 concentrations while minimizing systemic toxicity.

A proline-rich polypeptide complex derived from bovine colostrum increases brain-derived neurotrophic factor levels to support immune and nervous system development.

Novel indoleamine 2,3-dioxygenase inhibitor compounds with improved pharmacokinetic properties.

LS3 peptides cross the blood-brain barrier to modulate BK channels, resolving synthesis complexity while treating hearing loss.

Plastoquinone SkQ1 reduces cataract morbidity by addressing insufficient antioxidant protection from natural vitamins.

Epinephrine pharmaceutical compositions utilize pH-raising agents to stabilize the solution and reduce degradant formation.

Aminophosphinic derivatives inhibit neprilysin and aminopeptidase N to protect endogenous enkephalins, accelerating ocular healing.

Fluidized bed dry milling produces submicron diclofenac particles, eliminating wet grinding contamination and flocculation while enhancing bioavailability.

Nanoparticles deliver biomimetic peptides to resolve the contradiction between target binding specificity and peptide half-life, enhancing anti-tumor efficacy.

A chimeric anti-drug antibody receptor targets and eliminates B cells producing anti-drug antibodies.

Purine analogs target CLK2 and CDK1 kinases to address elusive molecular sites within the spliceosome complex.

Laminin 511-E8 fragments enhance corneal endothelial cell adhesion, reducing thickness in bullous keratopathy treatment.

Antibodies bind active plasma kallikrein to inhibit enzymatic activity and treat retinal diseases.

A uridine-based composition promotes hyaluronic acid synthesis to restore ocular surface lubrication.

Monthly C3 inhibitor dosing reduces drusen progression to retinal atrophy by blocking complement cascade activity.

An aqueous Khaya senegalensis extract maintains collagen XVIII levels to restore skin firmness and elasticity.

Fas inhibitors block apoptotic signaling to preserve retinal ganglion cells and axon density, reducing inflammation-mediated tissue damage in glaucoma.

Adeno-associated virus particles deliver SLC26A4 gene constructs to express pendrin protein, restoring hearing function by repairing damaged hair cells.

Segmented cyclic peptides with optimized hydrophobicity inhibit CD36-mediated inflammation, resolving synthesis complexity trade-offs.

New fluorene derivatives overcome metabolic stability and solubility limits of Geldanamycin by optimizing substituent patterns.

PEO-PBO block copolymers adsorb onto hydrophobic silicone hydrogel lenses, reducing surface tension to prevent lipid deposits and stabilize tear films.

A cyclosporin A form 2 hydrogel formulation delivers the drug to anterior ocular tissues via subconjunctival injection.

Replacing butyllithium with sodium hydride reduces costs and impurities while increasing yield through optimized pH adjustments.

A cross-linked polymer matrix dissolves within hours to release active ingredients without surgical removal.

A spray-cured hydrogel layer adheres to the cornea to restore deturgescence and protect nerve fibers.

Purified amniotic membrane compositions suppress TGF-beta signaling to treat pathological angiogenesis.

Bicyclic sulfonamide phenols overcome insufficient efficacy of simpler analogs by enhancing CXCR2 antagonistic activity and pharmacokinetic profiles.

Single low pH high alcohol precipitation captures IgG and A1PI in one step, resolving yield losses from multi-stage fractionation.

CXCR4 antagonists block the CXCR4-SDF-1 axis, resolving low G-CSF success rates and extended treatment duration.

Azaphenalene compounds chelate transition metals to prevent aberrant protein misfolding, offering a therapeutic approach for neurodegenerative diseases.

Surface-treated microparticles aggregate in vivo to form consolidated pellets, resolving rapid dispersal and immunogenicity while maintaining vision clarity.

An IL-20 antagonist antibody blocks inflammatory signaling pathways to restore tear volume and inhibit corneal damage in dry eye disease.

Bicyclic compounds enhance eIF2B activity to restore translation initiation, resolving the trade-off between stress response activation and protein synthesis.

Modified amino acid sequences in synthetic peptides overcome bacterial resistance while promoting wound healing and reducing inflammation.

An oral osmotic delivery system incorporates release-enhancing agents to ensure complete drug solubility.

Topical apoEdp peptide eye drops inhibit heparanase and matrix metalloproteinases, reducing vascular leakage and retinal damage in diabetic retinopathy.

Novel condensed diazepine compounds inhibit autotaxin activity to modulate lysophosphatidic acid levels.

Simplifying the molecular structure of natural sterones reduces synthesis complexity while maintaining bioavailability and therapeutic efficacy.

HDAC4 represses MEF2-dependent gene expression to resolve the contradiction between pressure management and cell regeneration in glaucoma treatment.

Topical adipose-derived mesenchymal stem cells enhance tear fluid secretion and ocular surface health.

CCR3-targeted quantum dots locate spontaneous CNV invisible to standard angiography, enabling early detection before retinal invasion.

Modified digoxin derivatives target the alpha2 Na,K-ATPase isoform to reduce intra-ocular pressure while minimizing systemic toxicity.

Segmenting SGLT2 from SGLT1 via local quality allows plasma glucose reduction without gastrointestinal side effects.

Tropane urea derivatives inhibit 11βHSD1 enzyme activity, reducing local glucocorticoid conversion to treat metabolic syndrome and diabetes.